Psyence Biomedical Ltd (PBM)

$2.75 -0.16 (-5.50%)
Market Cap 2.98M
Revenue (ttm) 0.00
Net Income (ttm) 1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 62,900
Avg Vol 3,242,978
Day's Range N/A - N/A
Shares Out 1.02M
Stochastic %K 5%
Beta 1.64
Analysts Strong Buy
Price Target N/A

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 346 7764
Address:
121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
Jack_Horway
Jack_Horway Jun. 24 at 10:28 PM
$PBM added more since it went below my average ...come onn mannn
0 · Reply
Digger35
Digger35 Jun. 24 at 7:19 PM
$PBM 7k down to 700 quid ,was 2k up when I sold but bought more when price dropped now I've stopped putting more in until I recover this one gla
0 · Reply
Nosh
Nosh Jun. 24 at 5:32 PM
$PBM Add to a core...down more here than almost everything else on a glance. Letting it ride though for awhile. GLTY.
0 · Reply
Jbjb90
Jbjb90 Jun. 24 at 4:05 PM
$PBM just need some news and actual volume, the tiniest bit of buying and up it goes every time
0 · Reply
RuddyRolls
RuddyRolls Jun. 24 at 2:01 PM
$PBM sector on fire today, got to expect a little $DFTX love to come our way shortly. We are the most leveraged psychedelics bet available for those who've made bank and want to reinvest some of the profits.
2 · Reply
STWCommenter
STWCommenter Jun. 23 at 9:07 PM
$PBM Oops. Still bullish, just wondering why they’ve been silent for over a month during a time where the policy tailwinds are so strong.
0 · Reply
ProfProfit
ProfProfit Jun. 23 at 8:05 PM
$PBM 🤦‍♂️
1 · Reply
Jbjb90
Jbjb90 Jun. 22 at 8:16 PM
$PBM havent read the whole thing cause im stuck at work, but the first thing that jumped out to me was 7mil cash/equivalents and enough to fund 12+ months
1 · Reply
Jbjb90
Jbjb90 Jun. 22 at 8:14 PM
$PBM https://www.stocktitan.net/sec-filings/PBM/20-f-psyence-biomedical-ltd-files-annual-report-foreign-issuer-6506def4909d.html
0 · Reply
RuddyRolls
RuddyRolls Jun. 22 at 2:22 AM
$PBM the $2.50 floor held for a very long run last year before the ascent to $20. Since then the sector has has nothing but profoundly positive news + the value of the Psyence holding has risen significantly given its ibogaine license. Phase 2 read out ever closer. In short this is a clear bottom level that I have strong conviction will hold firm. Buying zone is now! Load up your wheel barrow.
0 · Reply
Latest News on PBM
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Jun 16, 2026, 10:00 AM EDT - 8 days ago

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

2026-05-15T14:51:49.000Z - 5 weeks ago

Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

May 15, 2026, 9:15 AM EDT - 5 weeks ago

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical provides update on position in global ibogaine market

2026-04-20T12:19:33.000Z - 2 months ago

Psyence Biomedical provides update on position in global ibogaine market

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Apr 20, 2026, 7:42 AM EDT - 2 months ago

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Why Is Psyence Biomedical Stock (PBM) Up Today?

2026-04-18T00:33:00.000Z - 2 months ago

Why Is Psyence Biomedical Stock (PBM) Up Today?

Psyence Biomedical Ltd trading resumes

2026-04-17T19:16:22.000Z - 2 months ago

Psyence Biomedical Ltd trading resumes

Psyence Biomedical Ltd trading halted, volatility trading pause

2026-04-17T19:12:01.000Z - 2 months ago

Psyence Biomedical Ltd trading halted, volatility trading pause

Psyence acknowledges reports on U.S. action to advance Ibogaine research

2026-04-17T13:26:00.000Z - 2 months ago

Psyence acknowledges reports on U.S. action to advance Ibogaine research

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Apr 17, 2026, 9:15 AM EDT - 2 months ago

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Apr 8, 2026, 9:15 AM EDT - 2 months ago

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Mar 11, 2026, 9:15 AM EDT - 3 months ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Psyence Biomedical announces export of psilocybin to Australia

2026-03-03T14:22:48.000Z - 4 months ago

Psyence Biomedical announces export of psilocybin to Australia

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Mar 3, 2026, 9:15 AM EST - 4 months ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Feb 20, 2026, 5:20 PM EST - 4 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Psyence Biomedical announces results of annual, special meeting

2026-02-17T14:27:42.000Z - 4 months ago

Psyence Biomedical announces results of annual, special meeting

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 17, 2026, 9:15 AM EST - 4 months ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Feb 13, 2026, 6:30 PM EST - 4 months ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Psyence Biomedical announces settlement of shareholder litigation

2026-02-11T14:20:57.000Z - 4 months ago

Psyence Biomedical announces settlement of shareholder litigation

Psyence BioMed Announces Settlement of Shareholder Litigation

Feb 11, 2026, 9:15 AM EST - 4 months ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 28, 2026, 6:30 PM EST - 5 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 22, 2026, 1:42 PM EST - 5 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 20, 2026, 7:19 AM EST - 5 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 12, 2026, 8:30 AM EST - 5 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Jan 5, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 19, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Dec 9, 2025, 7:00 AM EST - 7 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 25, 2025, 7:00 AM EST - 7 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 20, 2025, 7:00 AM EST - 7 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 12, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 6, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Nov 3, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Aug 28, 2025, 8:00 AM EDT - 10 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 25, 2025, 5:00 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Jack_Horway
Jack_Horway Jun. 24 at 10:28 PM
$PBM added more since it went below my average ...come onn mannn
0 · Reply
Digger35
Digger35 Jun. 24 at 7:19 PM
$PBM 7k down to 700 quid ,was 2k up when I sold but bought more when price dropped now I've stopped putting more in until I recover this one gla
0 · Reply
Nosh
Nosh Jun. 24 at 5:32 PM
$PBM Add to a core...down more here than almost everything else on a glance. Letting it ride though for awhile. GLTY.
0 · Reply
Jbjb90
Jbjb90 Jun. 24 at 4:05 PM
$PBM just need some news and actual volume, the tiniest bit of buying and up it goes every time
0 · Reply
RuddyRolls
RuddyRolls Jun. 24 at 2:01 PM
$PBM sector on fire today, got to expect a little $DFTX love to come our way shortly. We are the most leveraged psychedelics bet available for those who've made bank and want to reinvest some of the profits.
2 · Reply
STWCommenter
STWCommenter Jun. 23 at 9:07 PM
$PBM Oops. Still bullish, just wondering why they’ve been silent for over a month during a time where the policy tailwinds are so strong.
0 · Reply
ProfProfit
ProfProfit Jun. 23 at 8:05 PM
$PBM 🤦‍♂️
1 · Reply
Jbjb90
Jbjb90 Jun. 22 at 8:16 PM
$PBM havent read the whole thing cause im stuck at work, but the first thing that jumped out to me was 7mil cash/equivalents and enough to fund 12+ months
1 · Reply
Jbjb90
Jbjb90 Jun. 22 at 8:14 PM
$PBM https://www.stocktitan.net/sec-filings/PBM/20-f-psyence-biomedical-ltd-files-annual-report-foreign-issuer-6506def4909d.html
0 · Reply
RuddyRolls
RuddyRolls Jun. 22 at 2:22 AM
$PBM the $2.50 floor held for a very long run last year before the ascent to $20. Since then the sector has has nothing but profoundly positive news + the value of the Psyence holding has risen significantly given its ibogaine license. Phase 2 read out ever closer. In short this is a clear bottom level that I have strong conviction will hold firm. Buying zone is now! Load up your wheel barrow.
0 · Reply
Jbjb90
Jbjb90 Jun. 18 at 10:45 PM
$PBM will be looking to add first thing Monday, not heave selling pressure, just a slow bleed, badly need news
0 · Reply
longjohntrader
longjohntrader Jun. 17 at 5:08 PM
$PBM tick tack added Yesterday and today too
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 17 at 5:15 AM
$PBM
0 · Reply
longjohntrader
longjohntrader Jun. 16 at 4:15 PM
$PBM today finally added. Some value here. Volume down...
0 · Reply
Jbjb90
Jbjb90 Jun. 16 at 3:00 PM
$PBM they badly need to put out some news to stop the slow bleed
0 · Reply
smalltraderjoe
smalltraderjoe Jun. 16 at 2:48 PM
$PBM At this rate in next one month it will be less than a $ and one more r/s
0 · Reply
ProfProfit
ProfProfit Jun. 15 at 4:48 PM
$PBM this thing is brutal.
0 · Reply
longjohntrader
longjohntrader Jun. 12 at 8:41 AM
$PBM something very big soon
0 · Reply
Tradetime3472
Tradetime3472 Jun. 11 at 11:04 PM
$PBM pretty sure this is us … https://www.prnewswire.com/news-releases/optimi-health-secures-ibogaine-supply-and-commences-finished-drug-product-development-302794202.html
0 · Reply
RuddyRolls
RuddyRolls Jun. 11 at 9:46 PM
$PBM @Jbjb90 good to see them so well represented in Europe. An abundance of business development & talent & collaboration ops no doubt. Potential phase 3 money probably scouting there too! Conference coverage here. https://themicrodose.substack.com/p/dispatch-from-the-netherlands https://themicrodose.substack.com/p/dispatch-from-the-netherlands-part
0 · Reply
Jbjb90
Jbjb90 Jun. 11 at 12:23 PM
$PBM obvious this isnt really news but i try to post things they file https://www.stocktitan.net/sec-filings/PBM/schedule-13g-a-psyence-biomedical-ltd-amended-passive-investment-disc-88a8743726e6.html
0 · Reply
Jbjb90
Jbjb90 Jun. 11 at 12:08 PM
$PBM it was up to 3.80 on 70k volume premarket, based on the last two weeks volume it would appear some kind of news is dropping soon
1 · Reply